Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company, announced on Friday that it has received the 'No Action Indicated' classification subsequent to a routine inspection by the United States Food and Drug Administration (FDA) of Emmaus' Postmarketing Adverse Drug Experience (PADE) compliance programme.
The PADE programme intends to shield patients from poor quality, unsafe, and ineffective dugs via proactive compliance strategies and risk-based enforcement actions. The main aim of the programme is to ensure that accurate, reliable, and timely safety data is submitted to the FDA in compliance with postmarking laws and regulations.
The two and a half-day inspection by two FDA Consumer Safety Officers revealed no objectional condition or practice in the six years that Endari has been marketed and so awarded a 'No Action Indicated' (NAI) inspection classification.
Charles Stark, Pharm.D., chief scientific officer of Emmaus Life Sciences, Inc, said, 'Based on the 2019 FDA inspection results survey, this places Emmaus within the top 16% of all companies investigated in 2019. This exemplifies Emmaus' mission to provide the highest quality Endari(R) (L-glutamine oral powder) and monitor its safety for our patients living with Sickle Cell Disease. These outcomes were possible due to the consistent and dedicated compliance to FDA regulations around surveillance, receipt, evaluation, and timely reporting of safety data by the Safety and Regulatory colleagues at Emmaus (Rafael Razon, M.D. and Rajani Singh). In addition, Emmaus is grateful to APCER Life Sciences, our long-standing Pharmacovigilance business partner, for their continued support.'
Pfizer's Hympavzi (marstacimab-hncq) receives US FDA approval for Hemophilia A or B treatment
Capricor begins BLA submission for deramiocel in Duchenne muscular dystrophy
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
Biogen receives FDA Breakthrough Therapy Designation for felzartamab
Inspira Technologies develops new disposable kit for perfusion market
Ananda Developments PLC signs contract for Phase 1 PK study on MRX1
Teva's Prolia biosimilar candidate accepted for review by FDA and EMA
Boehringer receives Breakthrough Therapy designation for survodutide
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices